Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective
Fabien B. Vincent(Monash Medical Centre), Christian Marcelli(Université de Caen Normandie), Fabienne Mackay(QIMR Berghofer Medical Research Institute), Eric F. Morand(Novartis (Switzerland)), Xavier Mariette(Inserm), Kim Murphy(Australian Regenerative Medicine Institute)
Cited by 349
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
|Annals of the Rheumatic Diseases|2015|728
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726